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Chemically functionalized congeners of N6-phenyladenosine and I ,3-dipropyl-8-phenylxanthine have been 
covalently coupled to fatty acids, diglycerides, and a phospholipid. The lipid-drug conjugates inhibit R-[3H]- 
phenylisopropyladenosine binding to A,-adenosine receptors in rat cerebral cortex membranes. A xanthine- 
phosphatidylethanolamine conjugate bound with a Ki value of 19 nM. Various xanthine esters of low poten- 
cy are potential prodrugs. Amides of an adenosine amine congener (ADAC) with 18-carbon fatty acids ex- 
hibited Ki values at A,-adenosine receptors of 70 pM, representing a 130-fold enhancement over the affinity 
of the corresponding acetyl amide. The very high affinity of adenosine-lipid conjugates may be due to stabili- 
zation of these adducts in the phospholipid microenvironment of the receptor protein. 
Lipid; Adenosine receptor; Xanthine; Adenosine derivative; Lipid-drug conjugate; Prodrug 
1. INTRODUCTION 
Adenosine receptors are present on the external 
surface of cell membranes in a variety of organs, 
including heart, brain, kidneys, lungs and 
vasculature [ 11. Biochemical and physiological 
studies have defined the presence of two adenosine 
receptor subtypes. The AI- (inhibitory) and AZ- 
(stimulatory) receptor subtypes are linked to 
adenylate cyclase through guanine nucleotide 
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regulatory proteins [2]. Potent N6-alkyl and 
N6-aryl substituted adenosine agonist analogs are 
of interest as potential therapeutic agents (e.g. an- 
tihypertensive, anxiolytic, or antipsychotic 
agents). Despite the synthesis of highly potent 
[3-51 and, to some extent, selective agonists and 
antagonists, the development of new therapeutic 
agents has been limited by a lack of organ selec- 
tivity. 
We report here an approach to increasing affini- 
ty of adenosine receptor drugs through the syn- 
thesis of covalent lipid conjugates. Due to radically 
increased hydrophobicity, such lipid conjugates 
may have unique routes of biodistribution leading 
to tissue selectivity, as has been seen with other 
lipid-drug conjugates. In previous studies, con- 
jugation of lipids with antineoplastic drugs [6], L- 
dopa [7], GABA [8], and other drugs has led to 
prodrug schemes for intestinal uptake into the lym- 
phatic system or for crossing the blood-brain bai- 
rier. For example, a parenterally administered 
‘lymphotropic’ 1,3-distearoyl-glyceride derivative 
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of L-dopa [7] was shown to partition selectively in- 
to the brain relative to plasma and produce a 
favorable therapeutic level in vivo in rodents. It is 
necessary for L-dopa to be cleaved from this pro- 
drug derivative by enzymatic esterolysis at the site 
of action. In another example, phospholipid con- 
jugates of immunomodulating muramyl peptides 
[141 have been used to target these drugs to 
macrophages in vivo. 
The functionalized congener approach to 
adenosine agonists [4,9] and antagonists [3,10,1 l] 
has created distal reactive sites on the drug 
molecules for generalized covalent attachment. We 
have synthesized lipid derivatives of such 
agonists/antagonists by this approach that, a 
priori, do not require cleavage at the site of action 
in order to be biologically active. Certain con- 
jugates display affinity at Ai-adenosine receptors 
far surpassing that of most p-substituted 
adenosines [9]. 
2. MATERIALS AND METHODS 
Lipid conjugates (table 1) of ADAC, compound 
4 [9], and XAC, compound 24 [lo], were syn- 
thesized either through acylation of the primary 
amino groups on the drug using fatty acid 
anhydrides or by carbodiimide condensation. The 
lipid derivatives were purified to chromatographic 
homogeneity, as judged using thin layer 
chromatography (silica, chloroform/methanol/ 
acetic acid, 85 : 10 : 5), either by crystallization 
(compounds 6-15, 26-28) or by preparative TLC 
(compounds 3, 17, 18, 21-23) using glass backed 
plates, 20 x 20 cm, 1OOOrm thick. IR, UV and 
300 MHz NMR spectra (measured on a Varian 
spectrophotometer by W. White and Dr H. Yeh, 
NIH) were consistent with the assigned structures. 
Lipid derivatives were stable to storage at - 10°C 
in the solid state for several months. 
2.1. Lipid amides of ADAC (compounds 6- 15) 
ADAC (40 mg, 0.07 mmol[9]) was suspended in 
5 ml dimethylformamide and treated with a solu- 
tion of the appropriate fatty acid anhydride 
(0.16 mmol) in 2 ml of methylene dichloride. The 
mixture was warmed to 40°C until the reaction was 
judged to be complete by thin layer 
chromatography (typically 10 min). The product 
98 
was isolated as a precipitate upon addition of 
methylene dichloride and ether. 
2.2. 1,3-Dimyristin-2-XCC (compound 17) 
1,3-Dimyristin (45.5 mg, 89pmol) and XCC 
([lo], 34 mg, 89 pmol) were added to 3 ml 
dimethylformamide containing 20%) v/v, 
chloroform (ethanol-free). Excess EDAC (50 mg) 
and 4-dimethylaminopyridine (20 mg) were added, 
and the mixture was stirred for 24 h. Additional 
chloroform (3 ml) was added and the mixture was 
extracted three times with phosphate buffer (pH 
7). The organic layer was evaporated and the 
residue was recrystallized from chloroform/meth- 
anol and washed with water. The crude yield was 
42 mg (49%). A homogeneous ample was obtain- 
ed by preparative thin layer chromatography 
(silica, CHClJMeOH/HOAc, 85 : 10 : 5). 
2.3. 1,2-Distearoyl-3-XCC-phosphatidylethanol- 
amine (compound 18) 
XCC [lo] was coupled to 1,2-distearoyl 
phosphatidylethanolamine (Calbiochem) using the 
EDAC method (see above, compound 17), and the 
product was purified by preparative TLC. 
2.4. Elaidic ester of 8-[2-hydroxyethyl(amino- 
[carbonylmethyloxyphenyll)l-1,3-dipropyl- 
xanthine (compound 22) 
8-[2-Hydroxyethyl(amino[carbonylmethyloxy- 
phenyl])]-1,3_dipropylxanthine ([ill, 74 mg, 
0.17 mmol) and elaidic anhydride (215 mg, 
0.39 mmol, Sigma, St Louis, MO) were added to 
an equivolume mixture of methylene dichloride 
and dimethylformamide (10 ml) and treated with 
4-dimethylaminopyridine (30 mg). After stirring 
for 1 day the reaction was shown by thin layer 
chromatography to have reached approx. 70% 
completion. Water was added, and the organic 
phase was washed successively with sodium bicar- 
bonate and sodium bisulfate. The organic layer 
was reduced in volume, and the product was 
purified by preparative thin layer chromatography 
(CHCls/MeOH/HOAc, 90: 5 : 5). A high Rf band 
was isolated and eluted with methanol/chloroform 
(1: 1). The solvent was evaporated, and the residue 
was collected and washed with a minimal amount 
of cold methanol. The NMR spectrum of the 
product (60 mg, 50% yield) was consistent with the 
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assigned structure. The IR spectra showed the ex- considerably less potent than the parent 
pected ester carbonyl resonance band. N6-phenyladenosine, 2. 
2.5. Xanthine lipid amides (compounds 26-28) 
The compounds were prepared by acylation of 
XAC using fatty acid anhydrides (see above) or by 
the following procedure for myristoyl-XAC, com- 
pound 26: XAC ([lo], 191 mg, 0.45 mmol), 
myristic acid (123 mg, 0.54 mmol) and l-hydrox- 
ybenzotriazole (60 mg, 1 eq.) were suspended in 
20 ml dimethylformamide. EDAC (0.18 g, 2 eq.) 
was added and the mixture was stirred for 24 h. 
Saturated sodium bicarbonate solution (40 ml) was 
added, the solids were collected by filtration, 
washed (HzO), and dried in vacua at 50°C. 
The product (0.28 g, 98% yield), melting at 
228-230°C was homogeneous by thin layer 
chromatography (Rr = 0.75, silica, CHCl3/ 
MeOH/HOAc, 85: 10:5). Analysis 
(C35H54N605.3/2Hz0) talc. 63.13% C, 8.63% H, 
12.62% N; found 63.19% C, 8.47% H, 12.30% N. 
Competitive binding assays on rat brain mem- 
branes were carried out as reported [3,1 I] using 
1 nM R-[3H]phenylisopropyladenosine (PIA) as 
the radioligand. The membrane homogenate was 
incubated in the presence of the test compound for 
90 min at 37°C in 50 mM Tris-HCI buffer at pH 
7.4. The membranes were filtered through What- 
man GF/B filters. ICSO values were determined in 
no less than three determinations, each done in 
triplicate, and converted to Ki values using a Kd 
value for [3H]PIA of 1.0 nM and the Cheng- 
Prusoff equation. Effects on cyclic AMP ac- 
cumulation in adipocyte and PC12 (pheochromo- 
cytoma) cell membranes were measured as 
described [ 121. 
3. RESULTS AND DISCUSSION 
The high potency of the adenosine amine con- 
gener (ADAC, 4) has been related to the presence 
of a distal amino group and two para-substituted 
aromatic rings in the functionalized chain [9]. The 
amino group is probably involved in an elec- 
trostatic interaction with an anionic site, such as a 
charged amino acid residue or a phospholipid in 
the membrane. The enhancing effect of a distal 
amino group on affinity at adenosine receptors has 
been noted also for xanthine antagonists [3]. 
Acylation of the terminal primary amino group of 
ADAC with a series of aliphatic carboxylic acids of 
various lengths gave amide derivatives 5-15. The 
potencies of these amides at Ai-adenosine recep- 
tors were found to be dependent upon the length of 
the attached carboxylic acid moiety. Long chain 
lipid conjugates, such as the 18carbon mono- 
olefinic elaidoyl derivative, 10 (fig.l), were ex- 
tremely potent at displacing [3H]PIA from brain 
membranes in comparison to simpler N-acyl 
derivatives or to N6-cyclohexyladenosine, 1. Hill 
coefficients for compounds lo-13 were in the 
range of 0.9 to 1 .O. Affinity for the Ai binding site 
was enhanced 130-fold upon extension of the fatty 
acid chain from acetyl-ADAC, 5, 11-fold less po- 
tent than ADAC, to stearoyl-ADAC. Lipids of 18 
carbon atoms (compounds 9-13) differing only in 
the number (between 0 and 3) and geometry of 
olefinic groups present displayed comparable 
potencies. Thus, enhancement of potency caused 
by conjugation with a lipid appears not to be af- 
fected greatly by steric factors on the receptor 
microenvironment. As shown in fig.1, potency of 
ADAC amides at Al-receptors increased gradually 
between lengths of eight (capryloyl-ADAC, com- 
pound 6) and twelve carbons (lauroyl-ADAC, 
compound 8). 
Synthetic yields and results of the binding assays 
(Partitioning of lipid-drug conjugates into the 
membranes (not in association with receptor) 
and/or intracellular internalization and/or forma- 
tion of micelles in solution would affect binding 
equilibrium, thus Ki values are to be taken as ap- 
parent values.) are shown in table 1. p-(Carbox- 
ymethyl)phenyladenosine [9] was coupled to 
distearoyl phosphatidylethanolamine to give the 
conjugate 3. This conjugate, used also for at- 
tempted receptor targeting of liposomes [14], was 
The amide of ADAC with a branched-chain, 
cyclic fatty acid (retinoic acid), 15, displayed very 
high potency. The longest amide synthesized, 
behenoyl-ADAC, 14, and to a much lesser extent, 
stearoyl-ADAC, 9, had unusual inhibition curves 
(fig.2). Compound 14 displaced [‘H]PIA binding 
at subnanomolar concentrations, but at increased 
concentrations (between 1 nM and 1 PM) the in- 
hibition of radiotracer binding at Ai sites was 
diminished (reaching a minimum at 30 nM). A 
plausible explanation for this unusual behavior is 
99 
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Table 1 
Structuresa and binding affinities of purine-lipid conjugates 
Compounds % yield Ki (nM) 
Adenosine derivatives 
1. N6-cyciohexyl (CHA) 
2. I@-phenyl 
CHzCONH-(CHZ)ZOPO~CH~CHOCO(CH~)I&H~ 
I 
CH2OCO(CH&CH3 
4. hP~H2C~NH(CH&NH-H (ADAC) 0.85 + 0.35 
6. ADAC-CO(CH&CH3 
7. ADAC-CO(CH&CH3 
8. ADAC-CO(CH&oCH3 
9. ADAC-CO(CHz)&H3 
10. ADAC-CO(CH2),CH = CH(CH&CH3 (trans) 
11. ADAC-CO(CH&CH = CH(CH&CH3 
12. ADAC-CO(CH&CH = CHCHzCH = CH(CH&CH3 
13. ADAC-CO(CH&CH = CHCHzCH = CHCHzCH = CHCHzCH3 
14. ADAC-CO(CH&oCH3 
15. ADAC-CO[-CH = C(CH&CH = CH]z CH3 @runs) 
Xanthine derivatives (1,3-dipropyl) 
16. 8 OCH2CO-OCH2CH3 (XCC-OEt) 
OCHKO-OCH[-CH20CO(CH2),2CH& 
OCH2CO-OCH2CHOCO(CH2)r&H3 
I 
CH~OCO(CHZ)MCH~ 
19. 8@CHzCO-NH(CHz)zOH 
OCHKO-NH(CH&OCO(CHz),&H3 
22. aOCH2CO-NH(CH&OCO(CH&CH = CH(CHWH3 (trans) 
w 
(continued) 
100 
43 84 + 4 
83 
22 
95 
90 
100 
83 
59 
89 
51 
30 
_ 42 k 3 
71 104 +- 7.7 
21 910 + 40 
_ 
63 
32 
70 
1.2 
3.2 k 0.5 
9.3 * 1.7 
5.8 t_ 1.2 
0.79 + 0.06 
0.217 + 0.027 
0.071 k 0.004 
0.069 f 0.008 
0.079 k 0.005 
0.082 + 0.005 
0.070 +_ 0.005 
0.39 + 0.03b 
0.13 + 0.02 
10.2 + 0.8 
16.3 f 1.3 
820 + 140 
121 + 13 
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23. 
24. 
25. 
26. 
27. 
28. 
8 ’ ’ 
0-O 
CH2CO-NH(CH&OPO&H~CHOCO(CH2)16CH~ - 
I 
CHzOCO(CH&CH3 
800 
’ ’ CHzCO-NH(CH&NH-H (XAC) 
0 
/ ’ OCHKO-NH(CH&NH-COCH3 (XAC-COCH$ - 
27 19 * 2 
_ 1.2 + 0.5 
- 24 2 3.5 
XAC-CO(CH&2CH3 98 98 f 16 
XAC-CO(CHz),CH = CHCHzCH = CH(CH&CH3 30 24 + 2.3 
XAC-COCHzNHCOCHNH-CO(CH2),CH = CHCHzCH = CH(CH2)zCH3 
I 
CH2 
0-CO(CH&CH = CHCH2CH = CH(CH&CH, 40 179 f 18 
a All olefin bonds are cis unless noted 
b Complex curve, see text 
that the longer straight-chain aliphatic conjugates Compounds 6, 9 and 10 at 100 nM were found 
may coalesce into micelles at critical concentra- to inhibit isoproterenol-stimulated adenylate 
tions as low as 1 nM, thus effectively removing cyclase through Al-adenosine receptors in 
ligand from solution. adipocyte membranes. Thus, these compounds 
loo 
f 
ii 5c 
3 
0 
Concentration Wl) 
Fig. 1. Effect of chain length of the fatty acid coupled to 
ADAC in the displacement of [3H]PIA from rat cerebral 
cortex membranes. No. of carbon atoms in lipid: 8, 
capryloyl-ADAC, compound 6 (0); 10, caproyl-ADAC, 
compound 7 (A); 12, lauroyl-ADAC, compound 8 (+); 
18, mono-olefin, elaidoyl-ADAC, compound 10 (A). 
b -x, 
‘9 I 9 I I 
.oj I)3 .I0 30 1.0 30 10 30 100 3w1ooo 
Concentration (rkl) 
Fig.2. Secondary rise in inhibition curves for long chain, 
saturated fatty acids coupled to ADAC in the 
displacement of [3H]PIA from rat cerebral cortex 
membranes. ADAC amide derivative: elaidoyl, 
compound 10, C-18, unsaturated (A); stearoyl, 
compound 9, C-18, saturated (+); behenoyl, compound 
14, C-22, saturated (0). 
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have agonist activity at Ar-adenosine receptors. In 
AZ-mediated stimulatory effects on adenylate 
cyclase in PC12 cells, compounds 9 and 10 were 
agonists with less than full efficacy (EC50 values of 
1.0 and 1.6pM, respectively). The adenosine 
derivatives 3 and 6, acting as partial agonists, and 
the xanthine derivative 23, acting as an antagonist, 
reversed the stimulatory effect of 5 ‘-N-ethyl- 
carboxamidoadenosine with Ka values of 380 + 30, 
570 + 50, and 295 + 30 nM, respectively. 
With xanthine-lipid conjugates, derived from 
XCC (compounds 17, 18 and’21-23) and XAC 
(compounds 25-28), the degree of receptor affini- 
ty observed for adenosine-lipid conjugates was not 
achieved. Among the xanthine conjugates are lipid 
derivatives of diverse structures, including glycerol 
esters (17, 18), fatty acid amides (26-28), esters 
(17, 18, 20-23), and a phospholipid derivative 
(23). A complex fatty acid bis-adduct (compound 
28) of a XAC-dipeptide (L-Tyr-Gly) is included. In 
this series, the xanthine-lipid conjugates of highest 
affinity at A1 receptors are the XCC amide of 
phosphatidylethanolamine, 23, and myristoyl- 
XAC, 27. The xanthine ester derivative, such as 
compound 21 of which the esterolysis product, 19, 
is considerably less potent, are designed as 
prodrugs. 
An explanation for the high potency of the fatty 
acid amide derivatives of ADAC may lie in the in- 
teraction of the pendant lipid with the 
phospholipid membrane in which the receptor pro- 
tein lies. Thus, the long hydrophobic group could 
act as a distal anchor in the membrane microen- 
vironment of the receptor. Such high potency in 
binding was not paralleled with xanthine 
derivatives. This may reflect a different orientation 
of the attached chain at the receptor binding site or 
a conformational difference between agonist and 
antagonist-occupied receptors. 
A catalytic mechanism of binding involving 
hydrophobic association of various amphiphilic 
peptide hormones with lipid membranes has been 
deduced [ 151. We have now shown that the poten- 
cy of an agent (adenosine) that acts at a discrete 
receptor protein at the cell surface may be en- 
hanced by covalent attachment to lipids. The 
potential use of these high affinity lipid derivatives 
for selective organ delivery currently is under in- 
vestigation. 
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